Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Cigna subsidiary Evernorth Health Services will authorize prior authorizations for GLP-1 weight-loss drugs under a new ...

The problem was resolved Thursday, when lawmakers sent a $240 million supplemental budget to Governor Maura Healey, which she ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

The popularity of GLP-1 drugs has insurance companies scrambling to satisfy consumer access while reining in exorbitant costs ...

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

Even if the order takes effect, it will do nothing to address the root causes of the problem it purports to solve.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, ...

Lilly shares sink after CVS Zepbound decision Lilly shares fell roughly 10% on Thursday. While the company has had strong sales of its weight loss and diabetes treatments, some investors were ...